{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:35:30Z","timestamp":1787668530224,"version":"build-2736575974"},"reference-count":106,"publisher":"Walter de Gruyter GmbH","issue":"6","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Parkinson\u2019s disease (PD) is a common neurodegenerative disorder affecting middle-aged and elderly individuals. Its clinical manifestations include both motor and non-motor symptoms. Traditionally, Lewy bodies (LBs), which are formed by misfolded \u03b1-synuclein (\u03b1-syn), have been regarded as the core pathological hallmark. It is believed that the selective damage to dopaminergic neurons in the nigrostriatal system by LBs constitutes the primary mechanism underlying motor symptoms. However, approximately 30\u201380\u202f% of PD patients also experience psychiatric and behavioral disturbances, such as anxiety, depression, cognitive impairment, and sleep disorders. The pathological mechanisms underlying these symptoms cannot be fully explained by \u03b1-syn alone. Recent biomarker studies have confirmed that hyperphosphorylated tau protein forms neurofibrillary tangles (NFTs) and amyloid \u03b2-protein (A\u03b2) plaques can coexist with \u03b1-syn in the brains of PD patients, especially in advanced stages. These coexisting pathologies show significant positive correlations with cognitive impairment and sleep disorders, suggesting that the neuropsychiatric symptoms in PD may result from the synergistic effects of multiple protein pathologies involving \u03b1-syn, tau, and A\u03b2. This review synthesizes these findings to propose an integrated \u201csynergistic co-pathogenic network\u201d of \u03b1-syn, tau, and A\u03b2, thereby providing a novel theoretical framework for developing precise, multi-target therapeutic strategies against PD-related neuropsychiatric disorders.<\/jats:p>","DOI":"10.1515\/revneuro-2026-0041","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:59:26Z","timestamp":1778666366000},"page":"619-636","source":"Crossref","is-referenced-by-count":2,"title":["Psychiatric and behavioral disorders in Parkinson\u2019s disease: co-pathogenic mechanisms of tau, A\u03b2, and \u03b1-synuclein proteins (narrative review)"],"prefix":"10.1515","volume":"37","author":[{"given":"Ju-Yuan","family":"Chai","sequence":"first","affiliation":[{"name":"The Department of Encephalopathy , The First Affiliated Hospital of Henan University of Chinese Medicine , Henan 450000 , China"},{"name":"The First Clinical Medical College of Henan University of Chinese Medicine , Henan 450000 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Department of Traditional Chinese Medicine , The Third Affiliated Hospital of Zhengzhou University , Henan 450000 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Qiang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Henan University of Chinese Medicine , Henan 450000 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Rui","family":"Ma","sequence":"additional","affiliation":[{"name":"Henan University of Chinese Medicine , Henan 450000 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Han","family":"Cao","sequence":"additional","affiliation":[{"name":"The Department of Encephalopathy , The First Affiliated Hospital of Henan University of Chinese Medicine , Henan 450000 , China"},{"name":"The First Clinical Medical College of Henan University of Chinese Medicine , Henan 450000 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Rui","family":"Zhu","sequence":"additional","affiliation":[{"name":"The Department of Encephalopathy , The First Affiliated Hospital of Henan University of Chinese Medicine , Henan 450000 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Zhi","family":"Ma","sequence":"additional","affiliation":[{"name":"The Department of Encephalopathy , The First Affiliated Hospital of Henan University of Chinese Medicine , Henan 450000 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Lin","family":"Luo","sequence":"additional","affiliation":[{"name":"The Department of Encephalopathy , The First Affiliated Hospital of Henan University of Chinese Medicine , Henan 450000 , China"},{"name":"The First Clinical Medical College of Henan University of Chinese Medicine , Henan 450000 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Li","family":"Zhan","sequence":"additional","affiliation":[{"name":"The Department of Encephalopathy , The First Affiliated Hospital of Henan University of Chinese Medicine , Henan 450000 , China"},{"name":"The First Clinical Medical College of Henan University of Chinese Medicine , Henan 450000 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Yan","family":"Fan","sequence":"additional","affiliation":[{"name":"The Department of Encephalopathy , The First Affiliated Hospital of Henan University of Chinese Medicine , Henan 450000 , China"},{"name":"The First Clinical Medical College of Henan University of Chinese Medicine , Henan 450000 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Lan","sequence":"additional","affiliation":[{"name":"The Department of Encephalopathy , The First Affiliated Hospital of Henan University of Chinese Medicine , Henan 450000 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"2026080410023548683_j_revneuro-2026-0041_ref_001","doi-asserted-by":"crossref","unstructured":"Akhtar, R.S., Xie, S.X., Chen, Y.J., Rick, J., Gross, R.G., Nasrallah, I.M., Van Deerlin, V.M., Trojanowski, J.Q., Chen-Plotkin, A.S., Hurtig, H.I., et al.. (2017). Regional brain amyloid-\u03b2 accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia. PLoS One 12: e0177924, https:\/\/doi.org\/10.1371\/journal.pone.0177924.","DOI":"10.1371\/journal.pone.0177924"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_002","doi-asserted-by":"crossref","unstructured":"Alam, P., Bousset, L., Melki, R., and Otzen, D.E. (2019). \u03b1-Synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities. J.\u00a0Neurochem. 150: 522\u2013534, https:\/\/doi.org\/10.1111\/jnc.14808.","DOI":"10.1111\/jnc.14808"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_003","doi-asserted-by":"crossref","unstructured":"Antico, O., Thompson, P.W., Hertz, N.T., Muqit, M.M.K., and Parton, L.E. (2025). Targeting mitophagy in neurodegenerative diseases. Nat. Rev. Drug. Discov. 24: 276\u2013299, https:\/\/doi.org\/10.1038\/s41573-024-01105-0.","DOI":"10.1038\/s41573-024-01105-0"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_004","doi-asserted-by":"crossref","unstructured":"Benveniste, H., Heerdt, P.M., Fontes, M., Rothman, D.L., and Volkow, N.D. (2019). Glymphatic system function in relation to anesthesia and sleep states. Anesth. Analg. 128: 747\u2013758, https:\/\/doi.org\/10.1213\/ane.0000000000004069.","DOI":"10.1213\/ANE.0000000000004069"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_005","doi-asserted-by":"crossref","unstructured":"Bloom, G.S. (2014). Amyloid-\u03b2 and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 71: 505\u2013508, https:\/\/doi.org\/10.1001\/jamaneurol.2013.5847.","DOI":"10.1001\/jamaneurol.2013.5847"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_006","doi-asserted-by":"crossref","unstructured":"Bohnen, N.I., Frey, K.A., Studenski, S., Kotagal, V., Koeppe, R.A., Constantine, G.M., Scott, P.J., Albin, R.L., and M\u00fcller, M.L. (2014). Extra-nigral pathological conditions are common in Parkinson\u2019s disease with freezing of gait: an in\u00a0vivo positron emission tomography study. Mov. Disord. 29: 1118\u20131124, https:\/\/doi.org\/10.1002\/mds.25929.","DOI":"10.1002\/mds.25929"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_007","doi-asserted-by":"crossref","unstructured":"Bol\u00f3s, M., Llorens-Mart\u00edn, M., Jurado-Arjona, J., Hern\u00e1ndez, F., R\u00e1bano, A., and Avila, J. (2016). Direct evidence of internalization of tau by microglia in\u00a0vitro and in\u00a0vivo. J.\u00a0Alzheimers Dis. 50: 77\u201387, https:\/\/doi.org\/10.3233\/jad-150704.","DOI":"10.3233\/JAD-150704"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_008","doi-asserted-by":"crossref","unstructured":"Brown, H.J., Fan, R.Z., Bell, R., Salehe, S.S., Mart\u00ednez, C.M., Lai, Y., and Tieu, K. (2025). Imbalanced mitochondrial dynamics in human PD and \u03b1-synuclein mouse brains. Neurobiol. Dis. 212: 106976, https:\/\/doi.org\/10.1016\/j.nbd.2025.106976.","DOI":"10.1016\/j.nbd.2025.106976"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_009","doi-asserted-by":"crossref","unstructured":"Chan, L., Chung, C.C., Hsieh, Y.C., Wu, R.M., and Hong, C.T. (2023). Plasma extracellular vesicle tau, \u03b2-amyloid, and \u03b1-synuclein and the progression of Parkinson\u2019s disease: a follow-up study. Ther. Adv. Neurol. Disord. 16: 17562864221150329, https:\/\/doi.org\/10.1177\/17562864221150329.","DOI":"10.1177\/17562864221150329"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_010","doi-asserted-by":"crossref","unstructured":"Cheng, Y., Tan, G., Zhu, Q., Wang, C., Ruan, G., Ying, S., Qie, J., Hu, X., Xiao, Z., Xu, F., et al.. (2023). Efficacy of fecal microbiota transplantation in patients with Parkinson\u2019s disease: clinical trial results from a randomized, placebo-controlled design. Gut Microbes 15: 2284247, https:\/\/doi.org\/10.1080\/19490976.2023.2284247.","DOI":"10.1080\/19490976.2023.2284247"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_011","doi-asserted-by":"crossref","unstructured":"Choi, B.K., Choi, M.G., Kim, J.Y., Yang, Y., Lai, Y., Kweon, D.H., Lee, N.K., and Shin, Y.K. (2013). Large \u03b1-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking. Proc. Natl. Acad. Sci. U. S. A. 110: 4087\u20134092, https:\/\/doi.org\/10.1073\/pnas.1218424110.","DOI":"10.1073\/pnas.1218424110"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_012","doi-asserted-by":"crossref","unstructured":"Chung, C.C., Chan, L., Chen, J.H., Bamodu, O.A., Chiu, H.W., and Hong, C.T. (2021). Plasma extracellular vesicles tau and \u03b2-amyloid as biomarkers of cognitive dysfunction of Parkinson\u2019s disease. Faseb J. 35: e21895, https:\/\/doi.org\/10.1096\/fj.202100787r.","DOI":"10.1096\/fj.202100787R"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_013","doi-asserted-by":"crossref","unstructured":"Chung, C.W., Song, Y.H., Kim, I.K., Yoon, W.J., Ryu, B.R., Jo, D.G., Woo, H.N., Kwon, Y.K., Kim, H.H., Gwag, B.J., et al.. (2001). Proapoptotic effects of tau cleavage product generated by caspase-3. Neurobiol. Dis. 8: 162\u2013172, https:\/\/doi.org\/10.1006\/nbdi.2000.0335.","DOI":"10.1006\/nbdi.2000.0335"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_014","doi-asserted-by":"crossref","unstructured":"Clinton, L.K., Blurton-Jones, M., Myczek, K., Trojanowski, J.Q., and LaFerla, F.M. (2010). Synergistic interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J.\u00a0Neurosci. 30: 7281\u20137289, https:\/\/doi.org\/10.1523\/jneurosci.0490-10.2010.","DOI":"10.1523\/JNEUROSCI.0490-10.2010"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_015","doi-asserted-by":"crossref","unstructured":"Compta, Y., Parkkinen, L., Kempster, P., Selikhova, M., Lashley, T., Holton, J.L., Lees, A.J., and Revesz, T. (2014). The significance of \u03b1-synuclein, amyloid-\u03b2 and tau pathologies in Parkinson\u2019s disease progression and related dementia. Neurodegener. Dis. 13: 154\u2013156, https:\/\/doi.org\/10.1159\/000354670.","DOI":"10.1159\/000354670"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_016","doi-asserted-by":"crossref","unstructured":"Credle, J.J., George, J.L., Wills, J., Duka, V., Shah, K., Lee, Y.C., Rodriguez, O., Simkins, T., Winter, M., Moechars, D., et al.. (2015). GSK-3\u03b2 dysregulation contributes to Parkinson\u2019s-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and \u03b1-synuclein. Cell Death Differ. 22: 838\u2013851, https:\/\/doi.org\/10.1038\/cdd.2014.179.","DOI":"10.1038\/cdd.2014.179"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_017","doi-asserted-by":"crossref","unstructured":"Dauvilliers, Y., Schenck, C.H., Postuma, R.B., Iranzo, A., Luppi, P.H., Plazzi, G., Montplaisir, J., and Boeve, B. (2018). REM sleep behaviour disorder. Nat. Rev. Dis. Primers 4: 19, https:\/\/doi.org\/10.1038\/s41572-018-0016-5.","DOI":"10.1038\/s41572-018-0016-5"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_018","doi-asserted-by":"crossref","unstructured":"Ding, J., Zhang, J., Wang, X., Zhang, L., Jiang, S., Yuan, Y., Li, J., Zhu, L., and Zhang, K. (2017). Relationship between the plasma levels of neurodegenerative proteins and motor subtypes of Parkinson\u2019s disease. J.\u00a0Neural. Transm. (Vienna) 124: 353\u2013360, https:\/\/doi.org\/10.1007\/s00702-016-1650-2.","DOI":"10.1007\/s00702-016-1650-2"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_019","doi-asserted-by":"crossref","unstructured":"Durante, V., de Iure, A., Loffredo, V., Vaikath, N., De Risi, M., Paciotti, S., Quiroga-Varela, A., Chiasserini, D., Mellone, M., Mazzocchetti, P., et al.. (2019). Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuospatial memory alteration. Brain 142: 1365\u20131385, https:\/\/doi.org\/10.1093\/brain\/awz065.","DOI":"10.1093\/brain\/awz065"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_020","doi-asserted-by":"crossref","unstructured":"Emre, M., Aarsland, D., Brown, R., Burn, D.J., Duyckaerts, C., Mizuno, Y., Broe, G.A., Cummings, J., Dickson, D.W., Gauthier, S., et al.. (2007). Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease. Mov. Disord. 22: 1689\u20131707, quiz 1837, https:\/\/doi.org\/10.1002\/mds.21507.","DOI":"10.1002\/mds.21507"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_021","doi-asserted-by":"crossref","unstructured":"Fan, R.Z., Guo, M., Luo, S., Cui, M., and Tieu, K. (2019). Exosome release and neuropathology induced by \u03b1-synuclein: new insights into protective mechanisms of Drp1 inhibition. Acta Neuropathol. Commun. 7: 184, https:\/\/doi.org\/10.1186\/s40478-019-0821-4.","DOI":"10.1186\/s40478-019-0821-4"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_022","doi-asserted-by":"crossref","unstructured":"Feigin, V.L., Vos, T., Nichols, E., Owolabi, M.O., Carroll, W.M., Dichgans, M., Deuschl, G., Parmar, P., Brainin, M., and Murray, C. (2020). The global burden of neurological disorders: translating evidence into policy. Lancet. Neurol. 19: 255\u2013265, https:\/\/doi.org\/10.1016\/s1474-4422(19)30411-9.","DOI":"10.1016\/S1474-4422(19)30411-9"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_023","doi-asserted-by":"crossref","unstructured":"Feijoo, C., Campbell, D.G., Jakes, R., Goedert, M., and Cuenda, A. (2005). Evidence that phosphorylation of the microtubule-associated protein tau by SAPK4\/p38delta at Thr50 promotes microtubule assembly. J.\u00a0Cell Sci. 118: 397\u2013408, https:\/\/doi.org\/10.1242\/jcs.01655.","DOI":"10.1242\/jcs.01655"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_024","doi-asserted-by":"crossref","unstructured":"Fowler, S.L., Behr, T.S., Turkes, E., O\u2019Brien, D.P., Cauhy, P.M., Rawlinson, I., Edmonds, M., Foiani, M.S., Schaler, A., Crowley, G., et al.. (2025). Tau filaments are tethered within brain extracellular vesicles in Alzheimer\u2019s disease. Nat. Neurosci. 28: 40\u201348, https:\/\/doi.org\/10.1038\/s41593-024-01801-5.","DOI":"10.1038\/s41593-024-01801-5"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_025","doi-asserted-by":"crossref","unstructured":"Gamblin, T.C., Chen, F., Zambrano, A., Abraha, A., Lagalwar, S., Guillozet, A.L., Lu, M., Fu, Y., Garcia-Sierra, F., LaPointe, N., et al.. (2003). Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer\u2019s disease. Proc. Natl. Acad. Sci. U. S. A. 100: 10032\u201310037, https:\/\/doi.org\/10.1073\/pnas.1630428100.","DOI":"10.1073\/pnas.1630428100"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_026","doi-asserted-by":"crossref","unstructured":"Gendron, T.F. and Petrucelli, L. (2009). The role of tau in neurodegeneration. Mol. Neurodegener. 4: 13, https:\/\/doi.org\/10.1186\/1750-1326-4-13.","DOI":"10.1186\/1750-1326-4-13"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_027","doi-asserted-by":"crossref","unstructured":"Griner, S.L., Seidler, P., Bowler, J., Murray, K.A., Yang, T.P., Sahay, S., Sawaya, M.R., Cascio, D., Rodriguez, J.A., Philipp, S., et al.. (2019). Structure-based inhibitors of amyloid beta core suggest a common interface with tau. Elife 8, https:\/\/doi.org\/10.7554\/elife.46924.","DOI":"10.7554\/eLife.46924"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_028","doi-asserted-by":"crossref","unstructured":"Han, G., Bai, K., Yang, X., Sun, C., Ji, Y., Zhou, J., Zhang, H., and Ding, Y. (2022). \u201cDrug-carrier\u201d synergy therapy for amyloid-\u03b2 clearance and inhibition of tau phosphorylation via biomimetic lipid nanocomposite assembly. Adv. Sci. (Weinh) 9: e2106072, https:\/\/doi.org\/10.1002\/advs.202106072.","DOI":"10.1002\/advs.202106072"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_029","doi-asserted-by":"crossref","unstructured":"Han, J., Fan, Y., Wu, P., Huang, Z., Li, X., Zhao, L., Ji, Y., and Zhu, M. (2021). Parkinson\u2019s disease dementia: synergistic effects of alpha-synuclein, tau, beta-amyloid, and iron. Front. Aging. Neurosci. 13: 743754, https:\/\/doi.org\/10.3389\/fnagi.2021.743754.","DOI":"10.3389\/fnagi.2021.743754"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_030","doi-asserted-by":"crossref","unstructured":"Hanagasi, H.A., Tufekcioglu, Z., and Emre, M. (2017). Dementia in Parkinson\u2019s disease. J.\u00a0Neurol. Sci. 374: 26\u201331, https:\/\/doi.org\/10.1016\/j.jns.2017.01.012.","DOI":"10.1016\/j.jns.2017.01.012"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_031","doi-asserted-by":"crossref","unstructured":"Harrass, S., Quansah, M., Kumar, S., Radzieta, M., Jayawardena, B., Jones, C., David, M., Heng, B., Elbourne, L.D.H., Amanquah, S., et al.. (2025). Lactobacilli probiotics prevent amyloid-beta fibril formation in\u00a0vitro. Probiotics Antimicrob. Proteins, https:\/\/doi.org\/10.1007\/s12602-025-10776-z.","DOI":"10.21203\/rs.3.rs-6505627\/v1"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_032","doi-asserted-by":"crossref","unstructured":"He, S., Ru, Q., Chen, L., Xu, G., and Wu, Y. (2024). Advances in animal models of Parkinson\u2019s disease. Brain Res. Bull. 215: 111024, https:\/\/doi.org\/10.1016\/j.brainresbull.2024.111024.","DOI":"10.1016\/j.brainresbull.2024.111024"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_033","doi-asserted-by":"crossref","unstructured":"Hernandez, P., Lee, G., Sjoberg, M., and Maccioni, R.B. (2009). Tau phosphorylation by cdk5 and Fyn in response to amyloid peptide Abeta (25-35): involvement of lipid rafts. J.\u00a0Alzheimers Dis. 16: 149\u2013156, https:\/\/doi.org\/10.3233\/jad-2009-0933.","DOI":"10.3233\/JAD-2009-0933"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_034","doi-asserted-by":"crossref","unstructured":"Holth, J.K., Fritschi, S.K., Wang, C., Pedersen, N.P., Cirrito, J.R., Mahan, T.E., Finn, M.B., Manis, M., Geerling, J.C., Fuller, P.M., et al.. (2019). The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science 363: 880\u2013884, https:\/\/doi.org\/10.1126\/science.aav2546.","DOI":"10.1126\/science.aav2546"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_035","doi-asserted-by":"crossref","unstructured":"Hu, X., Yang, Y., and Gong, D. (2017). Changes of cerebrospinal fluid A\u03b2(42), t-tau, and p-tau in Parkinson\u2019s disease patients with cognitive impairment relative to those with normal cognition: a meta-analysis. Neurol. Sci. 38: 1953\u20131961, https:\/\/doi.org\/10.1007\/s10072-017-3088-1.","DOI":"10.1007\/s10072-017-3088-1"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_036","doi-asserted-by":"crossref","unstructured":"Hughes, C.D., Choi, M.L., Ryten, M., Hopkins, L., Drews, A., Bot\u00eda, J.A., Iljina, M., Rodrigues, M., Gagliano, S.A., Gandhi, S., et al.. (2019). Picomolar concentrations of oligomeric alpha-synuclein sensitizes TLR4 to play an initiating role in Parkinson\u2019s disease pathogenesis. Acta Neuropathol. 137: 103\u2013120, https:\/\/doi.org\/10.1007\/s00401-018-1907-y.","DOI":"10.1007\/s00401-018-1907-y"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_037","doi-asserted-by":"crossref","unstructured":"Iqbal, K., Liu, F., and Gong, C.X. (2016). Tau and neurodegenerative disease: the story so far. Nat. Rev. Neurol. 12: 15\u201327, https:\/\/doi.org\/10.1038\/nrneurol.2015.225.","DOI":"10.1038\/nrneurol.2015.225"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_038","doi-asserted-by":"crossref","unstructured":"Irwin, D.J., Lee, V.M., and Trojanowski, J.Q. (2013). Parkinson\u2019s disease dementia: convergence of \u03b1-synuclein, tau and amyloid-\u03b2 pathologies. Nat. Rev. Neurosci. 14: 626\u2013636, https:\/\/doi.org\/10.1038\/nrn3549.","DOI":"10.1038\/nrn3549"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_039","doi-asserted-by":"crossref","unstructured":"Ishida, K., Yamada, K., Nishiyama, R., Hashimoto, T., Nishida, I., Abe, Y., Yasui, M., and Iwatsubo, T. (2022). Glymphatic system clears extracellular tau and protects from tau aggregation and neurodegeneration. J.\u00a0Exp. Med. 219, https:\/\/doi.org\/10.1084\/jem.20211275.","DOI":"10.1084\/jem.20211275"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_040","doi-asserted-by":"crossref","unstructured":"Ittner, L.M., Ke, Y.D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., W\u00f6lfing, H., Chieng, B.C., Christie, M.J., Napier, I.A., et al.. (2010). Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer\u2019s disease mouse models. Cell 142: 387\u2013397, https:\/\/doi.org\/10.1016\/j.cell.2010.06.036.","DOI":"10.1016\/j.cell.2010.06.036"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_041","doi-asserted-by":"crossref","unstructured":"Jankovic, J. and Tan, E.K. (2020). Parkinson\u2019s disease: etiopathogenesis and treatment. J.\u00a0Neurol. Neurosurg. Psychiatry 91: 795\u2013808, https:\/\/doi.org\/10.1136\/jnnp-2019-322338.","DOI":"10.1136\/jnnp-2019-322338"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_042","doi-asserted-by":"crossref","unstructured":"Jiang, P., Gan, M., Ebrahim, A.S., Lin, W.L., Melrose, H.L., and Yen, S.H. (2010). ER stress response plays an important role in aggregation of \u03b1-synuclein. Mol. Neurodegener. 5: 56, https:\/\/doi.org\/10.1186\/1750-1326-5-56.","DOI":"10.1186\/1750-1326-5-56"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_043","doi-asserted-by":"crossref","unstructured":"John, A. and Reddy, P.H. (2021). Synaptic basis of Alzheimer\u2019s disease: focus on synaptic amyloid beta, P-tau and mitochondria. Ageing Res. Rev. 65: 101208, https:\/\/doi.org\/10.1016\/j.arr.2020.101208.","DOI":"10.1016\/j.arr.2020.101208"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_044","doi-asserted-by":"crossref","unstructured":"Kang, J.E., Lim, M.M., Bateman, R.J., Lee, J.J., Smyth, L.P., Cirrito, J.R., Fujiki, N., Nishino, S., and Holtzman, D.M. (2009). Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 326: 1005\u20131007, https:\/\/doi.org\/10.1126\/science.1180962.","DOI":"10.1126\/science.1180962"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_045","doi-asserted-by":"crossref","unstructured":"Katunina, E. and Titova, N. (2017). The epidemiology of nonmotor symptoms in Parkinson\u2019s disease (cohort and other studies). Int. Rev. Neurobiol. 133: 91\u2013110.","DOI":"10.1016\/bs.irn.2017.05.012"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_046","doi-asserted-by":"crossref","unstructured":"Khan, S., Hassan, M.I., Shahid, M., and Islam, A. (2023). Nature\u2019s toolbox against tau aggregation: an updated review of current research. Ageing Res. Rev. 87: 101924, https:\/\/doi.org\/10.1016\/j.arr.2023.101924.","DOI":"10.1016\/j.arr.2023.101924"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_047","doi-asserted-by":"crossref","unstructured":"Krzystek, T.J., Banerjee, R., Thurston, L., Huang, J., Swinter, K., Rahman, S.N., Falzone, T.L., and Gunawardena, S. (2021). Differential mitochondrial roles for \u03b1-synuclein in DRP1-dependent fission and PINK1\/Parkin-mediated oxidation. Cell Death Dis. 12: 796, https:\/\/doi.org\/10.1038\/s41419-021-04046-3.","DOI":"10.1038\/s41419-021-04046-3"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_048","doi-asserted-by":"crossref","unstructured":"Kummer, M.P. and Heneka, M.T. (2014). Truncated and modified amyloid-beta species. Alzheimers Res. Ther. 6: 28, https:\/\/doi.org\/10.1186\/alzrt258.","DOI":"10.1186\/alzrt258"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_049","doi-asserted-by":"crossref","unstructured":"Leyns, C.E.G., Gratuze, M., Narasimhan, S., Jain, N., Koscal, L.J., Jiang, H., Manis, M., Colonna, M., Lee, V.M.Y., Ulrich, J.D., et al.. (2019). TREM2 function impedes tau seeding in neuritic plaques. Nat. Neurosci. 22: 1217\u20131222, https:\/\/doi.org\/10.1038\/s41593-019-0433-0.","DOI":"10.1038\/s41593-019-0433-0"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_050","doi-asserted-by":"crossref","unstructured":"Litvan, I., Aarsland, D., Adler, C.H., Goldman, J.G., Kulisevsky, J., Mollenhauer, B., Rodriguez-Oroz, M.C., Tr\u00f6ster, A.I., and Weintraub, D. (2011). MDS Task Force on mild cognitive impairment in Parkinson\u2019s disease: critical review of PD-MCI. Mov. Disord. 26: 1814\u20131824, https:\/\/doi.org\/10.1002\/mds.23823.","DOI":"10.1002\/mds.23823"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_051","doi-asserted-by":"crossref","unstructured":"Litvan, I., Goldman, J.G., Tr\u00f6ster, A.I., Schmand, B.A., Weintraub, D., Petersen, R.C., Mollenhauer, B., Adler, C.H., Marder, K., Williams-Gray, C.H., et al.. (2012). Diagnostic criteria for mild cognitive impairment in Parkinson\u2019s disease: Movement Disorder Society Task Force guidelines. Mov. Disord. 27: 349\u2013356, https:\/\/doi.org\/10.1002\/mds.24893.","DOI":"10.1002\/mds.24893"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_052","doi-asserted-by":"crossref","unstructured":"Liu, J., Jiang, J., Qiu, J., Wang, L., Zhuo, J., Wang, B., Sun, D., Yu, S., and Lou, H. (2022). Urolithin A protects dopaminergic neurons in experimental models of Parkinson\u2019s disease by promoting mitochondrial biogenesis through the SIRT1\/PGC-1\u03b1 signaling pathway. Food Funct. 13: 375\u2013385, https:\/\/doi.org\/10.1039\/d1fo02534a.","DOI":"10.1039\/D1FO02534A"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_053","doi-asserted-by":"crossref","unstructured":"Lorente-Pic\u00f3n, M. and Laguna, A. (2021). New avenues for Parkinson\u2019s disease therapeutics: disease-modifying strategies based on the gut microbiota. Biomolecules 11, https:\/\/doi.org\/10.3390\/biom11030433.","DOI":"10.3390\/biom11030433"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_054","doi-asserted-by":"crossref","unstructured":"L\u00f6vestam, S., Li, D., Wagstaff, J.L., Kotecha, A., Kimanius, D., McLaughlin, S.H., Murzin, A.G., Freund, S.M.V., Goedert, M., and Scheres, S.H.W. (2024). Disease-specific tau filaments assemble via polymorphic intermediates. Nature 625: 119\u2013125, https:\/\/doi.org\/10.1038\/s41586-023-06788-w.","DOI":"10.1038\/s41586-023-06788-w"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_055","doi-asserted-by":"crossref","unstructured":"Lu, J., Zhang, S., Ma, X., Jia, C., Liu, Z., Huang, C., Liu, C., and Li, D. (2020). Structural basis of the interplay between \u03b1-synuclein and tau in regulating pathological amyloid aggregation. J.\u00a0Biol. Chem. 295: 7470\u20137480, https:\/\/doi.org\/10.1074\/jbc.ra119.012284.","DOI":"10.1074\/jbc.RA119.012284"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_056","doi-asserted-by":"crossref","unstructured":"Luth, E.S., Stavrovskaya, I.G., Bartels, T., Kristal, B.S., and Selkoe, D.J. (2014). Soluble, prefibrillar \u03b1-synuclein oligomers promote complex I-dependent, Ca2+-induced mitochondrial dysfunction. J.\u00a0Biol. Chem. 289: 21490\u201321507, https:\/\/doi.org\/10.1074\/jbc.m113.545749.","DOI":"10.1074\/jbc.M113.545749"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_057","doi-asserted-by":"crossref","unstructured":"Manczak, M. and Reddy, P.H. (2012). Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer\u2019s disease neurons: implications for mitochondrial dysfunction and neuronal damage. Hum. Mol. Genet. 21: 2538\u20132547, https:\/\/doi.org\/10.1093\/hmg\/dds072.","DOI":"10.1093\/hmg\/dds072"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_058","doi-asserted-by":"crossref","unstructured":"Mehra, S., Sahay, S., and Maji, S.K. (2019). \u03b1-Synuclein misfolding and aggregation: implications in Parkinson\u2019s disease pathogenesis. Biochim. Biophys. Acta Proteins Proteom. 1867: 890\u2013908, https:\/\/doi.org\/10.1016\/j.bbapap.2019.03.001.","DOI":"10.1016\/j.bbapap.2019.03.001"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_059","doi-asserted-by":"crossref","unstructured":"Mishra, J., Bhatti, G.K., Sehrawat, A., Singh, C., Singh, A., Reddy, A.P., Reddy, P.H., and Bhatti, J.S. (2022). Modulating autophagy and mitophagy as a promising therapeutic approach in neurodegenerative disorders. Life Sci. 311: 121153, https:\/\/doi.org\/10.1016\/j.lfs.2022.121153.","DOI":"10.1016\/j.lfs.2022.121153"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_060","doi-asserted-by":"crossref","unstructured":"Morton, H., Kshirsagar, S., Orlov, E., Bunquin, L.E., Sawant, N., Boleng, L., George, M., Basu, T., Ramasubramanian, B., Pradeepkiran, J.A., et al.. (2021). Defective mitophagy and synaptic degeneration in Alzheimer\u2019s disease: focus on aging, mitochondria and synapse. Free Radic. Biol. Med. 172: 652\u2013667, https:\/\/doi.org\/10.1016\/j.freeradbiomed.2021.07.013.","DOI":"10.1016\/j.freeradbiomed.2021.07.013"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_061","doi-asserted-by":"crossref","unstructured":"M\u00fcller, M.L., Frey, K.A., Petrou, M., Kotagal, V., Koeppe, R.A., Albin, R.L., and Bohnen, N.I. (2013). \u03b2-Amyloid and postural instability and gait difficulty in Parkinson\u2019s disease at risk for dementia. Mov. Disord. 28: 296\u2013301, https:\/\/doi.org\/10.1002\/mds.25213.","DOI":"10.1002\/mds.25213"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_062","doi-asserted-by":"crossref","unstructured":"Nabizadeh, F., Pirahesh, K., and Ramezannezhad, E. (2023). Longitudinal striatal dopamine transporter binding and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau, and phosphorylated tau in Parkinson\u2019s disease. Neurol. Sci. 44: 573\u2013585, https:\/\/doi.org\/10.1007\/s10072-022-06440-x.","DOI":"10.1007\/s10072-022-06440-x"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_063","doi-asserted-by":"crossref","unstructured":"Naismith, S.L., Mowszowski, L., Diamond, K., and Lewis, S.J. (2013). Improving memory in Parkinson\u2019s disease: a healthy brain ageing cognitive training program. Mov. Disord. 28: 1097\u20131103, https:\/\/doi.org\/10.1002\/mds.25457.","DOI":"10.1002\/mds.25457"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_064","doi-asserted-by":"crossref","unstructured":"Neddens, J., Temmel, M., Flunkert, S., Kerschbaumer, B., Hoeller, C., Loeffler, T., Niederkofler, V., Daum, G., Attems, J., and Hutter-Paier, B. (2018). Phosphorylation of different tau sites during progression of Alzheimer\u2019s disease. Acta Neuropathol. Commun. 6: 52, https:\/\/doi.org\/10.1186\/s40478-018-0557-6.","DOI":"10.1186\/s40478-018-0557-6"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_065","doi-asserted-by":"crossref","unstructured":"Ono, K. and Watanabe-Nakayama, T. (2021). Aggregation and structure of amyloid \u03b2-protein. Neurochem. Int. 151: 105208, https:\/\/doi.org\/10.1016\/j.neuint.2021.105208.","DOI":"10.1016\/j.neuint.2021.105208"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_066","doi-asserted-by":"crossref","unstructured":"Pan, L., Li, C., Meng, L., Tian, Y., He, M., Yuan, X., Zhang, G., Zhang, Z., Xiong, J., Chen, G., et al.. (2022). Tau accelerates \u03b1-synuclein aggregation and spreading in Parkinson\u2019s disease. Brain 145: 3454\u20133471, https:\/\/doi.org\/10.1093\/brain\/awac171.","DOI":"10.1093\/brain\/awac171"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_067","doi-asserted-by":"crossref","unstructured":"Pan, L., Meng, L., He, M., and Zhang, Z. (2021). Tau in the pathophysiology of Parkinson\u2019s disease. J.\u00a0Mol. Neurosci. 71: 2179\u20132191, https:\/\/doi.org\/10.1007\/s12031-020-01776-5.","DOI":"10.1007\/s12031-020-01776-5"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_068","doi-asserted-by":"crossref","unstructured":"Peeraully, T., Yong, M.H., Chokroverty, S., and Tan, E.K. (2012). Sleep and Parkinson\u2019s disease: a review of case-control polysomnography studies. Mov. Disord. 27: 1729\u20131737, https:\/\/doi.org\/10.1002\/mds.25197.","DOI":"10.1002\/mds.25197"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_069","doi-asserted-by":"crossref","unstructured":"Portz, P. and Lee, M.K. (2021). Changes in Drp1 function and mitochondrial morphology are associated with the \u03b1-synuclein pathology in a transgenic mouse model of Parkinson\u2019s disease. Cells 10, https:\/\/doi.org\/10.3390\/cells10040885.","DOI":"10.3390\/cells10040885"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_070","doi-asserted-by":"crossref","unstructured":"Pradeepkiran, J.A., Hindle, A., Kshirsagar, S., and Reddy, P.H. (2022). Are mitophagy enhancers therapeutic targets for Alzheimer\u2019s disease? Biomed. Pharmacother. 149: 112918, https:\/\/doi.org\/10.1016\/j.biopha.2022.112918.","DOI":"10.1016\/j.biopha.2022.112918"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_071","doi-asserted-by":"crossref","unstructured":"Pradeepkiran, J.A., Islam, M.A., Sehar, U., Reddy, A.P., Vijayan, M., and Reddy, P.H. (2025). Impact of diet and exercise on mitochondrial quality and mitophagy in Alzheimer\u2019s disease. Ageing Res. Rev. 108: 102734, https:\/\/doi.org\/10.1016\/j.arr.2025.102734.","DOI":"10.1016\/j.arr.2025.102734"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_072","doi-asserted-by":"crossref","unstructured":"Prinz, M., Jung, S., and Priller, J. (2019). Microglia biology: one century of evolving concepts. Cell 179: 292\u2013311, https:\/\/doi.org\/10.1016\/j.cell.2019.08.053.","DOI":"10.1016\/j.cell.2019.08.053"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_073","doi-asserted-by":"crossref","unstructured":"Qu, Y., An, K., Wang, D., Yu, H., Li, J., Min, Z., Xiong, Y., Xue, Z., and Mao, Z. (2025). Short-chain fatty acid aggregates alpha-synuclein accumulation and neuroinflammation via GPR43-NLRP3 signaling pathway in a model Parkinson\u2019s disease. Mol. Neurobiol. 62: 6612\u20136625, https:\/\/doi.org\/10.1007\/s12035-025-04726-7.","DOI":"10.1007\/s12035-025-04726-7"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_074","doi-asserted-by":"crossref","unstructured":"Rapoport, M., Dawson, H.N., Binder, L.I., Vitek, M.P., and Ferreira, A. (2002). Tau is essential to beta -amyloid-induced neurotoxicity. Proc. Natl. Acad. Sci. U. S. A. 99: 6364\u20136369, https:\/\/doi.org\/10.1073\/pnas.092136199.","DOI":"10.1073\/pnas.092136199"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_075","doi-asserted-by":"crossref","unstructured":"Rawat, P., Sehar, U., Bisht, J., Selman, A., Culberson, J., and Reddy, P.H. (2022). Phosphorylated tau in Alzheimer\u2019s disease and other tauopathies. Int. J.\u00a0Mol. Sci. 23, https:\/\/doi.org\/10.3390\/ijms232112841.","DOI":"10.3390\/ijms232112841"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_076","doi-asserted-by":"crossref","unstructured":"Reddy, P.H., Manczak, M., Yin, X., and Reddy, A.P. (2018). Synergistic protective effects of mitochondrial division inhibitor 1 and mitochondria-targeted small peptide SS31 in Alzheimer\u2019s disease. J.\u00a0Alzheimers Dis. 62: 1549\u20131565, https:\/\/doi.org\/10.3233\/jad-170988.","DOI":"10.3233\/JAD-170988"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_077","doi-asserted-by":"crossref","unstructured":"Roberson, E.D., Halabisky, B., Yoo, J.W., Yao, J., Chin, J., Yan, F., Wu, T., Hamto, P., Devidze, N., Yu, G.Q., et al.. (2011). Amyloid-\u03b2\/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer\u2019s disease. J.\u00a0Neurosci. 31: 700\u2013711, https:\/\/doi.org\/10.1523\/jneurosci.4152-10.2011.","DOI":"10.1523\/JNEUROSCI.4152-10.2011"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_078","doi-asserted-by":"crossref","unstructured":"Roberson, E.D., Scearce-Levie, K., Palop, J.J., Yan, F., Cheng, I.H., Wu, T., Gerstein, H., Yu, G.Q., and Mucke, L. (2007). Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer\u2019s disease mouse model. Science 316: 750\u2013754, https:\/\/doi.org\/10.1126\/science.1141736.","DOI":"10.1126\/science.1141736"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_079","doi-asserted-by":"crossref","unstructured":"Ruffmann, C., Calboli, F.C., Bravi, I., Gveric, D., Curry, L.K., de Smith, A., Pavlou, S., Buxton, J.L., Blakemore, A.I., Takousis, P., et al.. (2016). Cortical Lewy bodies and A\u03b2 burden are associated with prevalence and timing of dementia in Lewy body diseases. Neuropathol. Appl. Neurobiol. 42: 436\u2013450, https:\/\/doi.org\/10.1111\/nan.12294.","DOI":"10.1111\/nan.12294"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_080","doi-asserted-by":"crossref","unstructured":"Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Ch\u00e9telat, G., Teunissen, C.E., Cummings, J., and van der Flier, W.M. (2021). Alzheimer\u2019s disease. Lancet 397: 1577\u20131590, https:\/\/doi.org\/10.1016\/s0140-6736(20)32205-4.","DOI":"10.1016\/S0140-6736(20)32205-4"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_081","doi-asserted-by":"crossref","unstructured":"Schrag, A., Siddiqui, U.F., Anastasiou, Z., Weintraub, D., and Schott, J.M. (2017). Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson\u2019s disease: a cohort study. Lancet. Neurol. 16: 66\u201375, https:\/\/doi.org\/10.1016\/s1474-4422(16)30328-3.","DOI":"10.1016\/S1474-4422(16)30328-3"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_082","doi-asserted-by":"crossref","unstructured":"Shafiei, S.S., Guerrero-Mu\u00f1oz, M.J., and Castillo-Carranza, D.L. (2017). Tau oligomers: cytotoxicity, propagation, and mitochondrial damage. Front. Aging. Neurosci. 9: 83, https:\/\/doi.org\/10.3389\/fnagi.2017.00083.","DOI":"10.3389\/fnagi.2017.00083"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_083","doi-asserted-by":"crossref","unstructured":"Siderowf, A., Xie, S.X., Hurtig, H., Weintraub, D., Duda, J., Chen-Plotkin, A., Shaw, L.M., Van Deerlin, V., Trojanowski, J.Q., and Clark, C. (2010). CSF amyloid \u03b2 1-42 predicts cognitive decline in Parkinson disease. Neurology 75: 1055\u20131061, https:\/\/doi.org\/10.1212\/wnl.0b013e3181f39a78.","DOI":"10.1212\/WNL.0b013e3181f39a78"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_084","doi-asserted-by":"crossref","unstructured":"Singh, B., Covelo, A., Martell-Mart\u00ednez, H., Nanclares, C., Sherman, M.A., Okematti, E., Meints, J., Teravskis, P.J., Gallardo, C., Savonenko, A.V., et al.. (2019). Tau is required for progressive synaptic and memory deficits in a transgenic mouse model of \u03b1-synucleinopathy. Acta Neuropathol. 138: 551\u2013574, https:\/\/doi.org\/10.1007\/s00401-019-02032-w.","DOI":"10.1007\/s00401-019-02032-w"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_085","doi-asserted-by":"crossref","unstructured":"Skorvanek, M., Goldman, J.G., Jahanshahi, M., Marras, C., Rektorova, I., Schmand, B., van Duijn, E., Goetz, C.G., Weintraub, D., Stebbins, G.T., et al.. (2018). Global scales for cognitive screening in Parkinson\u2019s disease: critique and recommendations. Mov. Disord. 33: 208\u2013218, https:\/\/doi.org\/10.1002\/mds.27233.","DOI":"10.1002\/mds.27233"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_086","doi-asserted-by":"crossref","unstructured":"Stancu, I.C., Cremers, N., Vanrusselt, H., Couturier, J., Vanoosthuyse, A., Kessels, S., Lodder, C., Br\u00f4ne, B., Huaux, F., Octave, J.N., et al.. (2019). Aggregated tau activates NLRP3-ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded tau pathology in\u00a0vivo. Acta Neuropathol. 137: 599\u2013617, https:\/\/doi.org\/10.1007\/s00401-018-01957-y.","DOI":"10.1007\/s00401-018-01957-y"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_087","doi-asserted-by":"crossref","unstructured":"Svenningsson, P., Westman, E., Ballard, C., and Aarsland, D. (2012). Cognitive impairment in patients with Parkinson\u2019s disease: diagnosis, biomarkers, and treatment. Lancet. Neurol. 11: 697\u2013707, https:\/\/doi.org\/10.1016\/s1474-4422(12)70152-7.","DOI":"10.1016\/S1474-4422(12)70152-7"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_088","doi-asserted-by":"crossref","unstructured":"Terrelonge, M.Jr., Marder, K.S., Weintraub, D., and Alcalay, R.N. (2016). CSF \u03b2-amyloid 1-42 predicts progression to cognitive impairment in newly diagnosed parkinson disease. J.\u00a0Mol. Neurosci. 58: 88\u201392, https:\/\/doi.org\/10.1007\/s12031-015-0647-x.","DOI":"10.1007\/s12031-015-0647-x"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_089","doi-asserted-by":"crossref","unstructured":"Terwel, D., Muyllaert, D., Dewachter, I., Borghgraef, P., Croes, S., Devijver, H., and Van Leuven, F. (2008). Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice. Am. J.\u00a0Pathol. 172: 786\u2013798, https:\/\/doi.org\/10.2353\/ajpath.2008.070904.","DOI":"10.2353\/ajpath.2008.070904"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_090","doi-asserted-by":"crossref","unstructured":"Ulmer, T.S., Bax, A., Cole, N.B., and Nussbaum, R.L. (2005). Structure and dynamics of micelle-bound human alpha-synuclein. J.\u00a0Biol. Chem. 280: 9595\u20139603, https:\/\/doi.org\/10.1074\/jbc.m411805200.","DOI":"10.1074\/jbc.M411805200"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_091","doi-asserted-by":"crossref","unstructured":"Vitek, G.E., Decourt, B., and Sabbagh, M.N. (2023). Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of Alzheimer disease. Expert Opin. Investig. Drugs 32: 89\u201394, https:\/\/doi.org\/10.1080\/13543784.2023.2178414.","DOI":"10.1080\/13543784.2023.2178414"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_092","doi-asserted-by":"crossref","unstructured":"Vossel, K.A., Zhang, K., Brodbeck, J., Daub, A.C., Sharma, P., Finkbeiner, S., Cui, B., and Mucke, L. (2010). Tau reduction prevents Abeta-induced defects in axonal transport. Science 330: 198, https:\/\/doi.org\/10.1126\/science.1194653.","DOI":"10.1126\/science.1194653"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_093","doi-asserted-by":"crossref","unstructured":"Wagner, J., Krauss, S., Shi, S., Ryazanov, S., Steffen, J., Miklitz, C., Leonov, A., Kleinknecht, A., G\u00f6ricke, B., Weishaupt, J.H., et al.. (2015). Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies. Acta Neuropathol. 130: 619\u2013631, https:\/\/doi.org\/10.1007\/s00401-015-1483-3.","DOI":"10.1007\/s00401-015-1483-3"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_094","doi-asserted-by":"crossref","unstructured":"Wang, Y., Cella, M., Mallinson, K., Ulrich, J.D., Young, K.L., Robinette, M.L., Gilfillan, S., Krishnan, G.M., Sudhakar, S., Zinselmeyer, B.H., et al.. (2015). TREM2 lipid sensing sustains the microglial response in an Alzheimer\u2019s disease model. Cell 160: 1061\u20131071, https:\/\/doi.org\/10.1016\/j.cell.2015.01.049.","DOI":"10.1016\/j.cell.2015.01.049"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_095","doi-asserted-by":"crossref","unstructured":"Wang, J., Dai, L., Chen, S., Zhang, Z., Fang, X., and Zhang, Z. (2024). Protein-protein interactions regulating \u03b1-synuclein pathology. Trends Neurosci. 47: 209\u2013226, https:\/\/doi.org\/10.1016\/j.tins.2024.01.002.","DOI":"10.1016\/j.tins.2024.01.002"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_096","doi-asserted-by":"crossref","unstructured":"Wang, G., Huang, Y., Chen, W., Chen, S., Wang, Y., Xiao, Q., Liu, J., Fung, V.S., Halliday, G., and Chen, S. (2016). Variants in the SNCA gene associate with motor progression while variants in the MAPT gene associate with the severity of Parkinson\u2019s disease. Parkinsonism Relat. Disord. 24: 89\u201394, https:\/\/doi.org\/10.1016\/j.parkreldis.2015.12.018.","DOI":"10.1016\/j.parkreldis.2015.12.018"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_097","doi-asserted-by":"crossref","unstructured":"Wang, P., Lan, G., Xu, B., Yu, Z., Tian, C., Lei, X., Meissner, W.G., Feng, T., Yang, Y., and Zhang, J. (2023a). \u03b1-Synuclein-carrying astrocytic extracellular vesicles in Parkinson pathogenesis and diagnosis. Transl. Neurodegener. 12: 40, https:\/\/doi.org\/10.1186\/s40035-023-00372-y.","DOI":"10.1186\/s40035-023-00372-y"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_098","doi-asserted-by":"crossref","unstructured":"Wang, Z., Zheng, Y., Cai, H., Yang, C., Li, S., Lv, H., Feng, T., and Yu, Z. (2023b). A\u03b21-42-containing platelet-derived extracellular vesicle is associated with cognitive decline in Parkinson\u2019s disease. Front. Aging. Neurosci. 15: 1170663, https:\/\/doi.org\/10.3389\/fnagi.2023.1170663.","DOI":"10.3389\/fnagi.2023.1170663"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_099","doi-asserted-by":"crossref","unstructured":"Wills, J., Jones, J., Haggerty, T., Duka, V., Joyce, J.N., and Sidhu, A. (2010). Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson\u2019s disease brains with and without dementia. Exp. Neurol. 225: 210\u2013218, https:\/\/doi.org\/10.1016\/j.expneurol.2010.06.017.","DOI":"10.1016\/j.expneurol.2010.06.017"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_100","doi-asserted-by":"crossref","unstructured":"Wu, J., Li, C.S., Huang, W.Y., Zhou, S.Y., Zhao, L.P., Li, T., Li, M.A., Zhang, M.X., Qiao, C.M., Zhao, W.J., et al.. (2025). Gut microbiota promote the propagation of pathologic \u03b1-syn from gut to brain in a gut-originated mouse model of Parkinson\u2019s disease. Brain Behav. Immun. 128: 152\u2013169, https:\/\/doi.org\/10.1016\/j.bbi.2025.04.001.","DOI":"10.1016\/j.bbi.2025.04.001"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_101","doi-asserted-by":"crossref","unstructured":"Xiang, J., Qian, Z., Xi, Y., Wei, Y., Wang, G., Liu, X., Wang, Z.H., Zhang, Z., Wu, S., and Ye, K. (2025). Immunotherapy against tau fragment diminishes AD pathology, improving synaptic function and cognition. Mol. Neurodegener. 20: 60, https:\/\/doi.org\/10.1186\/s13024-025-00854-9.","DOI":"10.1186\/s13024-025-00854-9"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_102","doi-asserted-by":"crossref","unstructured":"Xiang, J., Tang, J., Kang, F., Ye, J., Cui, Y., Zhang, Z., Wang, J., Wu, S., and Ye, K. (2024). Gut-induced alpha-synuclein and tau propagation initiate Parkinson\u2019s and Alzheimer\u2019s disease co-pathology and behavior impairments. Neuron 112: 3585\u20133601.e3585, https:\/\/doi.org\/10.1016\/j.neuron.2024.08.003.","DOI":"10.1016\/j.neuron.2024.08.003"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_103","doi-asserted-by":"crossref","unstructured":"Xue, L.J., Yang, X.Z., Tong, Q., Shen, P., Ma, S.J., Wu, S.N., Zheng, J.L., and Wang, H.G. (2020). Fecal microbiota transplantation therapy for Parkinson\u2019s disease: a preliminary study. Medicine (Baltimore) 99: e22035, https:\/\/doi.org\/10.1097\/md.0000000000022035.","DOI":"10.1097\/MD.0000000000022035"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_104","doi-asserted-by":"crossref","unstructured":"Yu, C.C., Lu, C.Y., Chen, M.H., Chen, Y.S., Lu, C.H., Lin, Y.Y., Chou, K.H., and Lin, W.C. (2021). Brain atrophy mediates the relationship between misfolded proteins deposition and cognitive impairment in Parkinson\u2019s disease. J.\u00a0Pers. Med. 11, https:\/\/doi.org\/10.3390\/jpm11080702.","DOI":"10.3390\/jpm11080702"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_105","doi-asserted-by":"crossref","unstructured":"Zempel, H., Thies, E., Mandelkow, E., and Mandelkow, E.M. (2010). Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous tau into dendrites, tau phosphorylation, and destruction of microtubules and spines. J.\u00a0Neurosci. 30: 11938\u201311950, https:\/\/doi.org\/10.1523\/jneurosci.2357-10.2010.","DOI":"10.1523\/JNEUROSCI.2357-10.2010"},{"key":"2026080410023548683_j_revneuro-2026-0041_ref_106","doi-asserted-by":"crossref","unstructured":"Zhang, M., Hu, R., Chen, H., Chang, Y., Ma, J., Liang, G., Mi, J., Wang, Y., and Zheng, J. (2015). Polymorphic cross-seeding amyloid assemblies of amyloid-\u03b2 and human islet amyloid polypeptide. Phys. Chem. Chem. Phys. 17: 23245\u201323256, https:\/\/doi.org\/10.1039\/c5cp03329b.","DOI":"10.1039\/C5CP03329B"}],"container-title":["Reviews in the Neurosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/revneuro-2026-0041\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/revneuro-2026-0041\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:08:48Z","timestamp":1785838128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/revneuro-2026-0041\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":106,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,4,23]]},"published-print":{"date-parts":[[2026,8,24]]}},"alternative-id":["10.1515\/revneuro-2026-0041"],"URL":"https:\/\/doi.org\/10.1515\/revneuro-2026-0041","relation":{},"ISSN":["0334-1763","2191-0200"],"issn-type":[{"value":"0334-1763","type":"print"},{"value":"2191-0200","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]}}}